Table 1.
Participants who completed the study (n=46) |
Participants selected for the comet assay (n=20) |
|||
---|---|---|---|---|
Mean | SEM | Mean | SEM | |
Age | 56.0 | 1.5 | 53.9 | 2.4 |
BMI | 29.1 | 0.9 | 28.3 | 0.9 |
Number | % of Total | Number | % of Total | |
Sex | ||||
Female | 34 | 73.9 | 12 | 60 |
Male | 12 | 26.1 | 8 | 40 |
Ethnicity | ||||
African-American | 14 | 30.4 | 5 | 25 |
Asian | 1 | 2.2 | 1 | 5 |
Caucasian | 30 | 65.2 | 14 | 70 |
Hispanic | 1 | 2.2 | 0 | 0 |
Genotype | ||||
XPD Codon 312 | ||||
Asn/Asn | 4 | 8.7 | 4 | 20 |
Asp/Asn | 22 | 47.8 | 14 | 70 |
Asp/Asp | 20 | 43.5 | 2 | 10 |
XPD Codon 751 | ||||
Gln/Gln | 9 | 19.6 | 7 | 35 |
Lys/Gln | 26 | 56.5 | 13 | 65 |
Lys/Lys | 11 | 23.9 | 0 | 0 |
GSTM1 | ||||
GSTM1-null | 19 | 41.3 | 9 | 45 |
GSTM1+ | 27 | 58.7 | 11 | 55 |
GSTT1 | ||||
GSTT1-null | 9 | 19.6 | 1 | 5 |
GSTT1+ | 37 | 80.4 | 19 | 95 |
Forty-six participants completed the study. For twenty of those participants, PBMCs were collected on the final day of each treatment period immediately before treatment consumption and at 3 and 6 hours after consumption, and PBMC samples were subsequently assessed for DNA strand breaks by the comet assay.